Bristol-Myers Squibb Company (NYSE:BMY) insider have most recently took part in a trading activity. On Dec 15, 2017 Samuels Theodore R. Ii, Director bought 4,000 shares having total worth of $249,200 at the price of $62.3 per share, following the transaction a total of 22,000 shares owned by Samuels Theodore R. Ii. Before this latest buy, Samuels Theodore R. Ii purchased BMY at 2 other times during the past twelve months, for a total investment of $10.17M at an average of $56.36 per share.
The stock has experienced a total of 2 insider trades in the past three months. These trades include 2 sell activities .Furthermore, over the past 12 months , the stock was traded 11 times by insiders. In 9 of these trades, the insider was a seller while an employee of the company was the buyer in 2 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.46% on Dec 15, 2017, hitting $62.42. 8,856,775 shares of the company’s stock traded hands. Bristol-Myers Squibb Company has a 52 week low of $46.82 and a 52 week high of $76.77. The company’s market cap is $93,130 million.
Bristol-Myers Squibb Company (NYSE:BMY) last announced its earnings results on Oct 26, 2017. The company reported 0.00 earnings per share (EPS) for the quarter, lower than the consensus estimate of 0.76 by $0.76., compared to the consensus estimate of $5,170 million. During the same quarter in the previous year, the company posted 0.77 earnings per share. The company’s revenue for the quarter was down 100% on a year-over-year basis.
|earnings per share||0.00||0.74||0.84||0.63||0.77||0.69||0.74||0.38||0.39||0.53|
Bristol-Myers Squibb Co, a Delaware corporation was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: BioPharmaceuticals. The Company’s pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes (typically involving recombinant DNA technology), called ‘biologics’. Small molecule drugs are typically administered orally, e.g., in the form of a pill or tablet, although other drug delivery mechanisms are used as well. Biologics are typically administered to patients through injections or by infusion. Its revenues come from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience and metabolics. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company’s key prodcts include, Plavix , Avapro , Eliquis , Reyataz , Sustiva Franchise , Baraclude , Sprycel, Yervoy, Orencia among others.The Company promotes its products directly to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and highly competitive. The Company competes with other research-based drug companies, many smaller research companies and generic drug manufacturers. The Company is subject to global regulation by regional, country, state and local agencies.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018